The United States market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high growth tech stocks ...
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
Zacks Small Cap Research on MSN6h
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Learn more about whether BioMarin Pharmaceutical Inc. or Exact Sciences Corporation is a better investment based on AAII's A+ ...
The market has been flat over the last week but is up 32% over the past year, with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for ...
In a report released on November 29, Uy Ear from Mizuho Securities maintained a Buy rating on Arcutis Biotherapeutics (ARQT – Research Report).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback